EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Quantification of Circulating Tumor DNA in Translocation‐Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants

A Schmid iD, U Lausch, A Runkel, J Kiefer, T Pauli, M Boerries, B Bogner, S U Eisenhardt, D Braig iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von A Schmid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Hand Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Liposarcoma, Myxoid, Translocation, Genetic, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Advanced Clinician Scientists (D.B.), Clinician Scientist (A.R., A.S.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myxoid liposarcomas (MLS) can exhibit a disseminated metastatic pattern, necessitating extensive diagnostics during follow‐up. With no tumor markers available, early diagnosis of recurrences and tumor monitoring is difficult. The detection of circulating tumor DNA (ctDNA; liquid biopsy) in MLS with the characteristic translocations t(12;16) and t(12;22) can provide an additional diagnostic. However, due to the often very low tumor fraction, distinguishing actual tumor variants from sequencing artifacts remains a key challenge.

Methods

Using MLS as a model for translocation‐driven tumors, this study evaluates a refined analytical approach for detecting both single nucleotide variants (SNVs) and structural variants (SVs) with the highest possible sensitivity and specificity. Different analysis pipelines using Unique Molecular Identifiers (UMIs) were compared in dilution series of tumor DNA from MLS patients ( n = 11) and a cell line. The results were validated on plasma samples ( n = 36) from two MLS patients and one patient with Synovial Sarcoma (SS).

Results

In dilution series, the use of UMIs significantly reduced false positive events in SNV analysis while maintaining high sensitivity without significant differences. In SV analysis, the effect of UMIs was not consistently detectable, as some dilution series exhibited no false positive events even without UMI correction. Additional filter criteria further improved specificity without significantly compromising assay sensitivity. Validation on patient plasma samples confirmed these findings, demonstrating the advantages of the differentiated analytical approach.

Conclusion

By integrating a refined analytical approach for SNVs and SVs, we achieved reliable ctDNA detection that corresponded with the clinical course of the patients’ disease. This method enables non‐invasive tumor detection in translocation‐driven tumors with low mutational burden and can easily be adapted into routine clinical diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALiposarcoma, MyxoidTranslocation, GeneticPolymorphism, Single NucleotideBiomarkers, TumorChromosome BreakpointsHumansFemaleMaleMiddle AgedAdultHigh-Throughput Nucleotide SequencingLiquid BiopsyCell Line, Tumor

Stichwörter der Autor:innen

diagnostic biomarkerliquid biopsymyxoid liposarcomanext‐generation sequencingsoft tissue sarcoma

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Plastic and Hand Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Radiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: A Schmid, D Braig

Förderung

  • Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg
  • Advanced Clinician Scientists (D.B.)
  • Clinician Scientist (A.R., A.S.)
  • Deutsche Forschungsgemeinschaft
  • Dres. Bayer Stiftung

Zitieren

APA

Schmid, A., Lausch, U., Runkel, A., Kiefer, J., Pauli, T., Boerries, M., Bogner, B., Eisenhardt, S. U., & Braig, D. (2025). Improved Quantification of Circulating Tumor DNA in Translocation‐Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants. Cancer Medicine. https://doi.org/10.1002/cam4.70704

Vancouver

Schmid A, Lausch U, Runkel A, Kiefer J, Pauli T, Boerries M, et al. Improved Quantification of Circulating Tumor DNA in Translocation‐Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants. Cancer Medicine. 2025. doi:10.1002/cam4.70704

BibTeX
@article{Schmid2025,
  author = {Schmid, A and Lausch, U and Runkel, A and Kiefer, J and Pauli, T and Boerries, M and Bogner, B and Eisenhardt, S U and Braig, D},
  title = {Improved Quantification of Circulating Tumor DNA in Translocation‐Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70704}
}
Kostenlos starten →